Psilocybin vs Ketamine for Alcohol Use Disorder
University of Iowa
Summary
This study will collect data that measures the effects of a psychedelic intervention on patients struggling with alcohol use disorder (AUD). The study design will be a double blind, randomized, active-comparator trial with two study arms. Subjects randomized to Arm 1 (n=40) will receive individual psychotherapy sessions plus a 30 mg dose of psilocybin. Arm 2 subjects (n=40) will receive individual psychotherapy sessions and a 0.75 mg/kg dose of ketamine.
Eligibility
- Age range
- 21–65 years
- Sex
- All
- Healthy volunteers
- No
Inclusion criteria: * Weight between 50kg and 150kg * No known allergies to rescue medication * For people capable of becoming pregnant, not pregnant and using contraception * Not currently breastfeeding * Meets criteria for DSM-V moderate to severe AUD. * Have at least 4 heavy drinking days (5 or more standard drinks in a day) in the past 30 days. * Not currently participating in formal treatment for AUD. * No history of a of cerebrovascular accident, asthma, or significant alcohol withdrawal history * No seizure disorder, coronary artery disease, heart failure, uncontrolled hypertension, in…
Interventions
- DrugPsilocybin
30 mg single dose
- DrugKetamine
0.75 mg/kg weight-based single dose
Location
- University of Iowa Health CareIowa City, Iowa